Table 2.
Comparison between participants requiring hospitalization and those who did not.
| Not Hospitalized N = 55 |
Hospitalized N = 21 |
p | |
|---|---|---|---|
| Age | 58.4 ± 16.5 | 60.1 ± 14.6 | 0.696 |
| Male gender | 35 (63.6) | 12 (57.1) | 0.609 |
| Coronary heart disease | 7 (12.7) | 2 (9.5) | 1 |
| Heart failure | 9 (16.4) | 1 (4.8) | 0.268 |
| COPD/asthma | 8 (14.5) | 3 (14.3) | 1 |
| Diabetes mellitus | 15 (27.3) | 3 (14.3) | 0.366 |
| Chronic kidney disease | 16 (29.1) | 5 (23.8) | 0.778 |
| Autoimmune disease | 2 (3.6) | 3 (14.3) | 0.126 |
| Solid organ malignancy | 6 (10.9) | 10 (47.6) | 0.001 |
| Hematological malignancy | 34 (61.8) | 16 (76.2) | 0.288 |
| HSCT recipient | 4 (7.3) | 0 (0) | 0.571 |
| Solid organ transplant recipient | 18 (32.7) | 3 (14.3) | 0.153 |
| SARS-CoV-2 vaccination | 0.673 | 0.213 | |
| Unvaccinated | 1 (1.8) | 0 (0) | |
| One dose | 2 (3.6) | 1 (4.8) | |
| Two doses | 7 (12.7) | 2 (9.5) | |
| Three doses | 20 (36.4) | 5 (23.8) | |
| Four doses | 16 (29.1) | 7 (33.3) | |
| Five doses | 2 (3.6) | 3 (14.3) | |
| TXG/CIL dose | 1 | ||
| 150 mg/150 mg | 53 (96.4) | 20 (95.2) | |
| 300 mg/300 mg | 2 (3.6) | 1 (4.8) | |
| Previous COVID-19 infection | 17 (30.9) | 1 (4.8) | 0.017 |
| Hybrid immunity | 17 (30.9) | 1 (4.8) | 0.017 |
p < 0.05 denotes statistical significance and appears in bold. COPD: chronic obstructive pulmonary disease, HSCT: hematopoietic stem cell transplantation, and TXG/CIL: tixagevimab/cilgavimab.